52 stories
Tirzepatide is Eli Lilly's GLP-1/GIP dual agonist, sold as Mounjaro for type-2 diabetes and Zepbound for obesity. The Phase 3 SURMOUNT and SURPASS programs established it as the most potent incretin therapy approved.
SURMOUNT-5, the head-to-head against semaglutide, read out in April 2026 with 21.6% mean weight loss at 72 weeks versus 15.4% for semaglutide; 36.2% of tirzepatide patients hit ≥25% weight loss versus 19.4% on semaglutide. The drug also has FDA approval for moderate-to-severe obstructive sleep apnea via the SURMOUNT-OSA program, and Truveta EHR data presented at OMA 2026 reproduced the head-to-head signal in routine 12-month care.
Like semaglutide, tirzepatide sits on the FDA's April 30, 2026 proposal to exclude branded actives from the 503B bulks list. Stories here track new readouts, the head-to-head economics, and the long compounding fight.
Tirzepatide (Mounjaro) Indian sales fell to ₹114 crore in March from ₹135 crore in February, while semaglutide sales rose to ₹59 crore. Semaglutide's GLP-1 segment share jumped to 33% from 25% as dozens of generics flood the market.
Research in JAMA Network Open shows semaglutide, tirzepatide, and bariatric surgery all produce substantial fat mass reduction but also cause reductions in lean mass over 24 months, highlighting the body composition tradeoff in GLP-1 treatment.
Based on analysis of 107,910 patients, the FDA concluded there is no increased suicide risk associated with GLP-1 medications and has requested removal of related warning labels.
Injectable semaglutide and tirzepatide will drop to ~$350/month initially and $245/month within two years, down from current list prices of $1,000–$1,350/month.
Analysis of the FAERS database (2012–2025) examining exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide reveals distinct risk profiles, suggesting not all GLP-1 agents carry the same safety concerns.
Analyst deep-dive into Lilly's position as healthcare's most valuable company, with ~60% U.S. incretin market share driven by tirzepatide and a retatrutide pipeline showing ~30% weight loss potential.
The ATTAIN-MAINTAIN trial demonstrated that patients switching from injectable semaglutide or tirzepatide to oral orforglipron maintained their weight loss.
At APhA2026, semaglutide's FLOW trial showed 24% reduction in major kidney events in CKD patients, while tirzepatide's SURMOUNT-OSA trial demonstrated dramatic reductions in sleep apnea severity.
Patients switching from dulaglutide to tirzepatide reported greater improvement in weight-related self-perception at week 40, highlighting benefits beyond glycemic control.
CancerNetwork reviews the latest evidence on thyroid cancer risk associated with GLP-1 RAs like Ozempic and Mounjaro, providing clinicians with an updated risk-benefit assessment for long-term prescribing.
Pharmacist guide on new self-pay pricing for tirzepatide, navigating insurance and medication switching, with warnings against unsafe compounded GLP-1 products.
A BMJ-published study of over 600,000 US veterans found GLP-1 medications tied to reduced risk of substance use disorders across all major addictive substances, plus reduced overdose and death risk.
New research shows semaglutide, dulaglutide, and tirzepatide can increase testosterone levels in men with obesity, adding another ancillary benefit to the GLP-1 portfolio.
Both pharma giants reached most-favored-nation pricing agreements with the Trump Administration to reduce costs of tirzepatide and semaglutide for American consumers.
A panel of 21 obesity and cancer experts proposed a 5,000-participant, decade-long trial to test whether semaglutide and tirzepatide can prevent obesity-related cancers.
A Cleveland Clinic analysis of 7,938 adults who discontinued semaglutide or tirzepatide found that real-world outcomes are better than clinical trials suggested. Obesity patients regained just 0.5% of body weight on average after one year, and 45% either maintained or continued losing weight by restarting treatment, switching medications, or adopting lifestyle changes.